share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43

派珀·桑德勒維持對Supernus Pharmicals的增持,將目標股價提高至43美元
Benzinga ·  2023/11/09 14:56

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $42 to $43.

派珀·桑德勒分析師戴維·阿姆塞勒維持Supernus Pharmicals(納斯達克股票代碼:SUPN)增持 “增持”,並將目標股價從42美元上調至43美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論